Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more here.
Reaching the halfway point in the Phase 1B trial, Solexan™ shows promise as a novel topical therapy to ease shingles pain and accelerate recovery.
Wintermute Biomedical is thrilled to announce a significant milestone in our Phase 1B clinical trial for Solexan™, our novel topical therapy for shingles. We have now reached the halfway point, with 15 patients completing recruitment. This achievement marks a crucial step toward developing an innovative treatment designed to alleviate the acute pain caused by shingles.
The Phase 1B clinical trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and preliminary efficacy of Solexan™. Our goal is to address the unmet need for a treatment that reduces shingles-related pain and accelerates recovery. With its novel mechanism of action, Solexan™ has the potential to revolutionize antiviral treatment and improve patient outcomes.
The trial involves adult participants diagnosed with shingles and focuses on key endpoints, including pain reduction, lesion healing time, and overall patient comfort. With 15 patients already enrolled and actively participating, we are steadily progressing toward completing this critical phase of development.
Shingles (herpes zoster) is a painful condition caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. For many, shingles can lead to complications such as postherpetic neuralgia (PHN), a chronic pain condition that severely impacts quality of life. According to the CDC, approximately one in three people in the United States will develop shingles during their lifetime.
Solexan™ aims to mitigate acute pain and potentially reduce the risk of long-term complications. If successful, this treatment could redefine shingles management, offering relief to millions of patients worldwide.
This milestone reflects Wintermute Biomedical’s commitment to advancing innovative healthcare solutions. Leveraging our novel fatty acid platform and Solexan™'s robust antiviral properties demonstrated in preclinical studies, we believe this therapy is a promising candidate for addressing herpesvirus infections.
Learn more about shingles prevention and treatment through the CDC’s resources, and explore insights on postherpetic neuralgia from the National Institute on Aging.
As we continue with the trial, Wintermute Biomedical remains focused on rigorous research and patient safety. We are optimistic about the potential of Solexan™ to bring relief and improve lives. The results from this trial will inform our next steps and bring us closer to offering a revolutionary treatment for shingles.
Stay tuned for more updates as we progress toward completing this important study. For additional information about our clinical trials and other innovative projects, please visit our Research and Development page.